Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01966445
Title Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors GlaxoSmithKline
Indications
Therapies
Age Groups: adult
Covered Countries USA | NLD | AUS

Facility Status City State Zip Country Details
GSK Investigational Site Aurora Colorado 80045 United States Details
GSK Investigational Site New York New York 10065 United States Details
GSK Investigational Site Salt Lake City Utah 84112 United States Details
GSK Investigational Site Heidelberg Victoria 3084 Australia Details
GSK Investigational Site Melbourne Victoria 3004 Australia Details
GSK Investigational Site Nedlands Western Australia 6009 Australia Details
GSK Investigational Site Amsterdam 1066 CX Netherlands Details
GSK Investigational Site Amsterdam 1066 C Netherlands Details
GSK Investigational Site Groningen 9713 GZ Netherlands Details
GSK Investigational Site Groningen 9713 G Netherlands Details
GSK Investigational Site Nijmegen 6525 GA Netherlands Details
GSK Investigational Site Nijmegen 6525 G Netherlands Details
GSK Investigational Site Rotterdam 3075 EA Netherlands Details
GSK Investigational Site Rotterdam 3075 E Netherlands Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field